Profile of etravirine in the treatment of HIV in pediatrics

References

• United Nations Programme on HIV/AIDS. 2010 Global Report. Available from: http://www.unaids.org. Accessed June 27, 2013.
   Google Scholar
• Kourtis A, Lee F, Abrams E, Jamieson D, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis. 2006;6:726–732.
   PubMed Web of Science ®Google Scholar
• Kourtis A, Jamieson D, de Vincenzi I, et al. Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments. Am J Obstet Gynecol. 2007;197: S113-S122.
   Web of Science ®Google Scholar
• Soeiro R, Rubinstein A, Rashbaum W, Lyman W Maternofetal transmission of AIDS: frequency of human immunodeficiency virus type 1 nucleic acid sequences in human fetal DNA. J Infect Dis. 1992;166:699–703.
   Web of Science ®Google Scholar
• Auger I, Thomas P, De Gruttola V, et al. Incubation periods for paediatric AIDS patients. Nature. 1988;336:575–577.
   PubMed Web of Science ®Google Scholar
• Abrams E, Weedon J, Steketee R, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. J Infect Dis. 1998;178:101–108.
   PubMed Web of Science ®Google Scholar
• Blanche S, Newell M, Mayaux M, et al. Morbidity and mortality in European children vertically infected by HIV-1: the French pediatric HIV infection study group and European collaborative study. J AIDS. 1997;14:442–450.
   Web of Science ®Google Scholar
• Sandberg J, Fast N, Jordan K, et al. HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. J Immunol. 2003;170:4403–4410.
   Web of Science ®Google Scholar
• Ye P Kirschner D, Kourtis A. The thymus during HIV disease: role in pathogenesis and in immune recovery. J Immunol. 2004;170:4403–4410.
   Google Scholar
• Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599–604.
   PubMed Web of Science ®Google Scholar
• de Martino M, Tovo P, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000;284:190–197.
   Google Scholar
• Viani R, Araneta M, Deville J, Spector S. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:725–731.
   PubMed Web of Science ®Google Scholar
• Resino S, Rosino R, Bellón J, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis. 2006;43:243–252.
   PubMed Web of Science ®Google Scholar
• Violari A, Cotton M, Gibb D, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–2244.
   PubMed Web of Science ®Google Scholar
• Gona P, Van Dyke R, Williams P, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292–300.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Guidelines for the use of antiretroviral agents in Pediatric HIV infection. Available from: http://aidsinfo.nih. gov/contentfiles/Ivguidelines/pediatricguidelines.pdf. Accessed June 27, 2013.
   Google Scholar
• U.S. Food and Drug Administration. Approval of etravirine for treatment-experienced adult patients. Available from: http://www.fda. gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDS- Activities/ucm124019.htm. Accessed June 27, 2013.
   Google Scholar
• Tibotec Inc. Intelence (etravirine) tablets for oral use. Full prescribing information. Available from: http://www.intelence.com/shared/product/intelence/prescribing-information.pdf. Accessed June 27, 2013.
   Google Scholar
• Delaugerre C, Rohban R, Simon A, et al. Resistance profile and crossresistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regime. J Med Virol. 2001;65:445–448.
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773–12782.
   PubMed Web of Science ®Google Scholar
• Madruga J, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebocontrolled trial. Lancet. 2007;370:29–38.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomized, double-blind, placebocontrolled trial. Lancet. 2007;370:39–48.
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS. 2009;23:2289–2300.
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15:1045–1052.
   PubMed Web of Science ®Google Scholar
• Chandwani S, Koenig L, Sill A, et al. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health. 2012;51:242–251.
   PubMed Web of Science ®Google Scholar
• Menson E, Walker A, Sharland M, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort study. BMJ. 2006;332:1183–1187.
   PubMedGoogle Scholar
• Königs C, Feiterna-Sperling C, Esposito S, et al. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents. AIDS. 2012;26:447–455.
   Web of Science ®Google Scholar
• Starr S, Fletcher C, Spector S, et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:659–663.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Intelence (etravirine): pediatric dosing recommendations and new scored 25 mg tablet for pediatric dosing. U.S. Food and Drug Administration. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ HIVandAIDSActivities/ucm297471.htm. Accessed June, 29 2013.
   Google Scholar
• Schöller-Gyüre M, Kakuda T, van Sollingen-Ristea R. Bioavailability of the 100 mg etravirine tablet dispersed in water and of the 25 mg pediatric tablet formulation. Abstract M0PE0184 presented at the XVIIth International AIDS Conference, August 3–8, 2008, Mexico City, Mexico.
   Google Scholar
• Izurieta P, Kakuda T, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 2011;12:257–258.
   PubMed Web of Science ®Google Scholar
• Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012;59:245–253.
   PubMed Web of Science ®Google Scholar
• Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008;9:214–220.
   PubMed Web of Science ®Google Scholar
• Benaboud, Ekouevi DK, Urien S, et al. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2011;55:331–339.
   PubMed Web of Science ®Google Scholar
• Lamorde M, Byakika-Kibwika P, 0kaba-Kayom V, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr. 2010;55:345–350.
   PubMed Web of Science ®Google Scholar
• Else L, Taylor S, Back D, Khoo S. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther. 2011;16:1139–1147.
   PubMed Web of Science ®Google Scholar
• Gingelmaier A, Kurowski M, Kästner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 2006;20:1737–1743.
   PubMed Web of Science ®Google Scholar
• Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuviritide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS. 2009;23:434–435.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Valencia A, Martin-Peña R, Torres-Comejo A, et al. Intracellular and plasma pharmacokinetics of 400 mg etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients. J Antimicrob Chemother. 2012;67:681–684.
   PubMed Web of Science ®Google Scholar
• Jaworsky D, Thompson C, Yudin M, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther. 2010;15:677–680.
   PubMed Web of Science ®Google Scholar
• Scholler-Gyure M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RMW. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48:561–574.
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Schöller-Gyüre M, Hoetelmans RMW. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther. 2010;15:817–829.
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Schöller-Gyüre M, Hoetelmans RMW. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011;50:25–39.
   PubMed Web of Science ®Google Scholar
• Kakuda T, Green B, Morrish G, et al. Population pharmacokinetics of etravirine in HIV-1 infected, treatment-experienced children and adolescents (6 to <18 years). Abstract TULBPE025 presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 17–20, 2011, Rome, Italy.
   Google Scholar
• Palladino C, Briz V González-Tomè MI, et al. Short communication: evaluation of the effect of enfuviritide in 11 HIV-1 vertically infected pediatric patients outside clinical trials. AIDS Res Hum Retroviruses. 2010;26:301–305.
   PubMed Web of Science ®Google Scholar
• Rosso R, Bernardini C, Bruzzone B, et al. Efficacy and safety of daru- navir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. Eur J Med Res. 2009;14:136–138.
   Web of Science ®Google Scholar
• Vigano A, Meroni L, Marchetti G, et al. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multi-drug resistant HIV-1. Antivir Ther. 2008;13:839–843.
   PubMed Web of Science ®Google Scholar
• Briz V, Palladino C, Navarro M, et al. Etravirine-based highly active antiretroviral therapy in HIV-1 infected paediatric patients. HIV Med. 2011;12:442–446.
   Web of Science ®Google Scholar
• Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Safety and efficacy of etravirine in HIV-1 infected, treatment experienced children and adolescents (6 to <18 years): week 24 primary analysis of the phase II PIANO study. Abstract TULBPE027 presented at the 6 th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 17–20, 2011, Rome, Italy.
   Google Scholar
• Tudor-Williams G, Cahn P Chokephaibulkit K, et al. Safety and efficacy of etravirine in HIV-1 infected, treatment-experienced children and adolescents: PIANO 48-week results. Abstract TUAB0204 presented at the XIX International AIDS Conference, July 22–27, 2012, Washington, DC.
   Google Scholar
• Penazzato M, Giaquinto C. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children. Drugs. 2011;71:2131–2149.
   Web of Science ®Google Scholar
• Vingerhoets J, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther. 2007;12 Suppl 1:S34.
   Google Scholar
• Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS. 2010;24:503–514.
   PubMed Web of Science ®Google Scholar
• Aulicino P, Rocco C, Mecikovsky D, et al. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveals an association between K103 N+L100I and L74V mutations. Antivir Ther. 2010;15:641–650.
   Web of Science ®Google Scholar
• Bannister W, Ruiz L, Cozzi-Lepri A, et al. Comparison of genotypic resistance profiles and virological responses between patients starting nevirapine and efavirenz in EuroSIDA. AIDS. 2008;22:367–376.
   Web of Science ®Google Scholar
• Germanaud D, Derache A, Traore M, et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother. 2010;65:118–124.
   PubMed Web of Science ®Google Scholar
• Puthanakit T, Jourdain G, Hongsiriwon S, et al. HIV-1 drug resistance mutations in children after failure of first-line non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 2010;11:565–572.
   PubMed Web of Science ®Google Scholar
• Vaz P, Chaix M, Jani I, et al. Risk of extended viral resistance in human immunodeficiency virus-1 infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J. 2009;28:e283–e287.
   Google Scholar
• Kekitinwa A, Friedman D, Coakley E, Lie Y, Granziano F. Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first-line ART. Abstract 891 presented at the 16th Conference on Retroviruses and Opportunistic Infections, February 8–11, 2009, Montréal, Canada.
   Google Scholar
• Tolle M, Howard L, Kirk B, Gomila A, Schwarzwald H, Anabwani G. Reverse transcriptase genotypes in Pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana. J Int Assoc Physicians AIDS Care (Chic). 2012;11:260–268.
   Google Scholar
• Kiertiburanakul S, Wiboonchutikul S, Sukasem C, Chantratita W, Sungkanuparph S. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J Clin Virol. 2010;47:330–334.
   PubMed Web of Science ®Google Scholar
• Taiwo B, Chaplin B, Penugonda S, et al. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res. 2010;8:194–198.
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov. TMC125-TiDP35-C239-Continued access to etravirine (ETR) in treatment experienced HIV-1 infected children and adolescents. Available from: http/www.clinicaltrials.gov. Accessed June 27, 2013.
   Google Scholar
• Clinical Trials.gov. Evaluating the safety and tolerability of etravirine in HIV-1 infected infants and children. Available from: http://clinicaltrials. gov/show/NCT01504841. Accessed June 26, 2013.
   Google Scholar
• Clinical Trials.gov. A study to assess the pharmacokinetics (blood levels) of TMC14 (darunavir) taken with ritonavir and/or TMC125 (etravirine) and TMC278 (rilpivirine) in HIV-1 infected pregnant women. Available from: http://clinicaltrials.gov/show/NCT00855335. Accessed June 26, 2013.
   Google Scholar
• Clinical Trials.gov. Pharmacokinetic effects of new antiretroviral drugs on children, adolescents and young adults. Available from: http://clinicaltrials.gov/show/NCT00977756. Accessed March 15, 2013.
   Google Scholar
• Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse transcriptase inhibitor etravirine in treatment-experienced HIV-1 -infected patients. Clin Pharmacol Ther. 2010;88:695–703.
   PubMed Web of Science ®Google Scholar